Touchlight shortlisted for Best Emerging UK Synthetic Biology Company.

We are delighted to announce that Touchlight has been shortlisted for the OBN 2016 Best Emerging UK Synthetic Biology Company.

The OBN Awards celebrate innovation and achievement across the UK life sciences industry and recognising achievements from emerging to late stage R&D companies as well as life sciences investors.

A judging panel comprising a range of industry experts has been assembled to decide the overall winner in each category, with the winning companies being announced at the OBN Awards Ceremony on Thursday 6th October at the Oxford Town Hall.

Read the full article here.

- ENDS -

About Touchlight

Touchlight is a privately-owned CDMO based in London, U.K., focused on the provision of DNA services and manufacture of enzymatically produced doggybone DNA (dbDNA™) to enable the development of genetic medicines. Touchlight provide rapid, enzymatic DNA development and manufacturing for all advanced therapy production, including mRNA, viral and non-viral gene therapy and DNA API. dbDNA is a minimal, linear, covalently closed structure, which eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies. Clients can be supported from pre-clinical through development and supply, to licencing and tech transfer for use in-house.

For more information please contact: